First Trust Advisors LP Has $328,000 Stock Position in Haemonetics Co. (NYSE:HAE)

First Trust Advisors LP lessened its position in Haemonetics Co. (NYSE:HAE - Free Report) by 83.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,198 shares of the medical instruments supplier's stock after selling 20,663 shares during the period. First Trust Advisors LP's holdings in Haemonetics were worth $328,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Haemonetics during the 4th quarter worth approximately $32,803,000. Groupama Asset Managment purchased a new stake in shares of Haemonetics in the fourth quarter worth about $19,520,000. Raymond James Financial Inc. acquired a new stake in Haemonetics in the fourth quarter valued at approximately $19,002,000. Thrivent Financial for Lutherans increased its stake in Haemonetics by 14.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock worth $98,716,000 after buying an additional 164,111 shares during the period. Finally, Boston Partners boosted its stake in Haemonetics by 27.5% during the 4th quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier's stock valued at $41,485,000 after acquiring an additional 115,506 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Stock Performance

HAE stock traded up $0.51 during mid-day trading on Thursday, reaching $69.16. 122,340 shares of the stock traded hands, compared to its average volume of 694,582. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $3.47 billion, a PE ratio of 27.21, a P/E/G ratio of 1.11 and a beta of 0.32. The business has a 50-day moving average of $62.84 and a two-hundred day moving average of $71.28.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business's revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.90 EPS. As a group, equities analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $95.00 to $68.00 in a report on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday. Barrington Research lowered their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC cut their target price on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, Raymond James reiterated a "strong-buy" rating and issued a $105.00 price target (down previously from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and a consensus target price of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.